Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan-Reference-Cited by-同舟云学术

Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan

Published:2018-08-16 Issue:8 Volume:13 Page:e0201956
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Tajiri Hitoshi,Motoya Satoshi,Kinjo Fukunori,Maemoto Atsuo,Matsumoto Takayuki,Sato Noriko,Yamada Hiroshi,Nagano Mieko,Susuta Yutaka,Ozaki Kunihiko,Kondo Kazuoki,Hibi Toshifumi

Funder

Mitsubishi Tanabe Pharma Corporation

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference26 articles.

1. Inflammatory bowel disease incidence: up, down or unchanged?;RF Logan;Gut,1998

2. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review;NA Molodecky;Gastroenterology,2012

3. Inflammatory bowel disease: an expanding global health problem;AE M’Koma;Clin Med Insights Gastroenterol,2013

4. An update on the epidemiology of inflammatory bowel disease in Asia;KT Thia;Am J Gastroenterol,2008

5. Inflammatory bowel disease in children: epidemiological analysis of the nationwide IBD registry in Japan;T Ishige;J Gastroenterol,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TNF inhibitors as a treatment of pediatric IBD;Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology;2024-08-20

2. Infliximab for medical induction of remission in Crohn's disease;Cochrane Database of Systematic Reviews;2023-11-20

3. Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan;PLOS ONE;2022-04-19

4. The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China;Frontiers in Pediatrics;2021-12-13

5. Anti-cytokine therapy and small molecule agents for the treatment of inflammatory bowel disease;European Cytokine Network;2021-12